<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jofin</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал инфектологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Infectology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-6732</issn><publisher><publisher-name>IPO “АIDSSPbR"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22625/2072-6732-2020-12-2-88-96</article-id><article-id custom-type="elpub" pub-id-type="custom">jofin-1052</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Выявление Вич-1, резистентных к антиретровирусным препаратам, среди жителей томской области с впервые диагностированной Вич-инфекцией</article-title><trans-title-group xml:lang="en"><trans-title>Detection of HIV-1 resistant to antiretroviral drugs among tomsk oblast population with newly diagnosed HIV-infection</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зырянова</surname><given-names>Д. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Zyryanova</surname><given-names>D. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>младший научный сотрудник </p><p>тел.: 8(383)363-48-40, доп. 22-41</p><p>Кольцово, Новосибирская область </p></bio><bio xml:lang="en"/><email xlink:type="simple">zyryanova_dp@vector.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Астахова</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Astakhova</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>младший научный сотрудник </p><p>тел.: 8(383)363-47-00 доп. 21-40</p><p>Кольцово, Новосибирская область </p></bio><bio xml:lang="en"/><email xlink:type="simple">astahova_em@vector.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гашникова</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Gashnikova</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>лаборант-исследователь </p><p>тел.: 8(383)363-47-00 доп. 21-40 Кольцово, Новосибирская область </p></bio><bio xml:lang="en"/><email xlink:type="simple">gashnikova_mp@vector.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исмаилова</surname><given-names>Т. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ismailova</surname><given-names>T. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-эпидемиолог, заведующая эпидемиологическим отделом </p><p>тел.: 8(3822)76-52-03  Томск </p></bio><bio xml:lang="en"/><email xlink:type="simple">gonya-doc@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бочаров</surname><given-names>Е. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Bocharov</surname><given-names>E. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ведущий научный сотрудник, д.м.н.</p><p> тел.: 8(383)363-47-00 доп. 21-40Кольцово, Новосибирская область </p></bio><bio xml:lang="en"/><email xlink:type="simple">bef37@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернов</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>главный врач, заслуженный врач Российской Федерации</p><p>тел.: 8(3822)47-03-98  Томск </p></bio><bio xml:lang="en"/><email xlink:type="simple">alex@aidscenter.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тотменин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Totmenin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующий лабораторией, к.б.н.</p><p> тел.: 8(383)363-47-00 доп. 21-40  Кольцово, Новосибирская область </p></bio><bio xml:lang="en"/><email xlink:type="simple">totmenin@vector.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гашникова</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gashnikova</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующая отделом, к.б.н.</p><p> тел.: 8(383)363-47-00 доп. 21-40; e-mail: nmgashnikova@gmail.com Кольцово, Новосибирская область </p></bio><bio xml:lang="en"/><email xlink:type="simple">ngash@vector.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственный научный центр вирусологии и биотехнологии «Вектор»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Research Center of Virology and Biotechnology «Vector»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Центр по профилактике и борьбе со СПИД и инфекционными заболеваниями Томской области</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tomsk Regional Center for Prevention and Control of AIDS</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>06</month><year>2020</year></pub-date><volume>12</volume><issue>2</issue><fpage>88</fpage><lpage>96</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зырянова Д.П., Астахова Е.М., Гашникова М.П., Исмаилова Т.Н., Бочаров Е.Ф., Чернов А.С., Тотменин А.В., Гашникова Н.М., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Зырянова Д.П., Астахова Е.М., Гашникова М.П., Исмаилова Т.Н., Бочаров Е.Ф., Чернов А.С., Тотменин А.В., Гашникова Н.М.</copyright-holder><copyright-holder xml:lang="en">Zyryanova D.P., Astakhova E.M., Gashnikova M.P., Ismailova T.N., Bocharov E.F., Chernov A.S., Totmenin A.V., Gashnikova M.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.niidi.ru/jofin/article/view/1052">https://journal.niidi.ru/jofin/article/view/1052</self-uri><abstract><sec><title>Цель</title><p>Цель: оценка распространения ВИЧ-1, резистентных к антиретровирусным препаратам, среди жителей Томской области с впервые выявленной ВИЧ-инфекцией.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Собрано 122 клинических образца периферической крови ВИЧ-инфицированных жителей Томской области, не принимавших антиретровирусные препараты. Для выделенных из клинических образцов ВИЧ-1 исследована нуклеотидная последовательность фрагментов генома, кодирующих протеазу и обратную транскриптазу вируса. Выполнен комплексный анализ эпидемиологических данных пациентов и наличия в геноме ВИЧ-1 мутаций, связанных с развитием резистентности к ингибиторам протеазы и обратной транскриптазы вируса.</p></sec><sec><title>Результаты</title><p>Результаты. Анализ ВИЧ-1, выделенных от наивных ВИЧ-инфицированных лиц Томской области, в 9,8% случаев выявил мутации ВИЧ-1, ассоциированные со снижением чувствительности вируса к антиретровирусным препаратам. Среди описанных мутаций 50%составляли мутации, связанные с резистентностью к ингибиторам протеазы вируса; в 33,3% – мутации резистентности к ненуклеозидным ингибиторам обратной транскриптазы и в 16,7% – к нуклеозидным ингибиторам обратной транскриптазы вируса. Из 9,8% резистентных вирусов в 7,3% случаев были выявлены мутации, ассоциированные с развитием потенциального/потенциально-низкого/низкого уровня снижения чувствительности ВИЧ-1 к препаратам. Основные мутации резистентности ВИЧ-1 высокого и среднего уровня были зарегистрированы лишь в 2,5% генотипированных ВИЧ-1, выделенных от лиц, потребляющих инъекционные наркотические препараты.</p></sec><sec><title>Заключение</title><p>Заключение. Выполненное исследование выявило среди наивных ВИЧ-инфицированных жителей Томской области достаточно низкую частоту регистрации ВИЧ-1, несущих мутации, ассоциированные с резистентностью к антиретровирусным препаратам. Вероятно это связано с относительно коротким периодом широкого применения в области  антиретровирусной терапии. Анализ эпидемиологических данных выявил факторы, негативно влияющие на прогноз дальнейшего развития эпидемии ВИЧ-инфекции в регионе – широкую распространенность практик рискованного поведения, способствующих передаче резистентных ВИЧ-1 как среди лиц, инфицированных при гетеросексуальных контактах, так и среди потребителей инъекционных наркотиков.</p></sec></abstract><trans-abstract xml:lang="en"><p>The purpose of this paper is to evaluate the spreading of HIV-1 resistant to antiretroviral drugs among Tomsk Oblast population with newly diagnosed HIV-infection.</p><sec><title>Materials and methods</title><p>Materials and methods. It was collected 122 clinical samples of  peripheral blood of HIV-infected patients from Tomsk Oblast who did not take antiretroviral drugs. In HIV-1 isolated from clinical samples we studied nucleotide sequence of genome fragments encoding virus protease and reverse transcriptase. Complex analyses of epidemiologic data from patients and the presence in genome HIV-1 mutations associated with resistance development to protease inhibitors and virus reverse transcriptase were carried out.</p></sec><sec><title>Results</title><p>Results. Analysis of HIV-1 isolated from Tomsk Oblast naïve HIV-infected population made it possible to detect HIV-1 mutations associated with a decrease of virus sensitivity to antiretroviral drugs in 9,8% of cases. Among described mutations 50% were associated with resistance to virus protease inhibitors; 33,3% were resistance mutations to nonnuclease inhibitors of reverse transcriptase, and 16.7% were resistance mutations to nucleoside inhibitors of virus reverse transcriptase. Out of 9,8% of resistant viruses 7,3% of casesincluded mutations associated with the development of potentially low level of reduction of HIV-1 sensitivity to drugs. Main HIV-1 resistance mutations of high and average levels were registered only in 2,5% of genotyped HIV-1 isolated from people who inject drugs.</p></sec><sec><title>Conclusion</title><p>Conclusion. Current study detected considerably low sampling rate of HIV-1 carrying mutations associated with resistance to antiretroviral drugs among Tomsk Oblast naïve HIV-infected population. It is believed to be caused by a relatively short period of extensive application of antiretroviral therapy in that territory. Analysis of epidemiologic data resulted in detection of factors negatively affecting prediction of further development of HIV-infection epidemic in the region including prevalence of risk behavior practice contributing to resistant HIV-1 transmission both among patients via heterosexual contacts and among people who inject drugs. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ВИЧ-1</kwd><kwd>передаваемая резистентность ВИЧ-1</kwd><kwd>Томская область</kwd></kwd-group><kwd-group xml:lang="en"><kwd>HIV-1</kwd><kwd>resistant HIV-1 transmission</kwd><kwd>Tomsk&#13;
Oblast</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Joint United Nations Programme on HIV/AIDS. 90-90-90. An ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland. – 2017. – UNAIDS. https://www.unaids.org/en/resources/documents/2017/90-90-90</mixed-citation><mixed-citation xml:lang="en">Joint United Nations Programme on HIV/AIDS. 90-90-90. An ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland. – 2017. – UNAIDS.  https://www.unaids.org/en/resources/documents/2017/90-90-90</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Viswanathan S, Justice A.C, Alexander G.C. et al. Adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2015; 69(4): 493–498. DOI: 10.1097/QAI.0000000000000643; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482798/</mixed-citation><mixed-citation xml:lang="en">Viswanathan S, Justice A.C, Alexander G.C. et al. Adherence and HIV RNA  suppression in the current era of highly active antiretroviral therapy. J Acquir  Immune Defic Syndr. 2015; 69(4): 493–498. DOI: 10.1097/QAI.0000000000000643; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482798/</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yang W.L., Kouyos R., Scherrer A.U. et al. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV Cohort Study from 1998 to 2012. J Infect Dis. 2015; 212(1): 28–38. DOI: 10.1093/infdis/jiv012. Epub 2015 Jan 9; https://www.ncbi.nlm.nih.gov/pubmed/25576600</mixed-citation><mixed-citation xml:lang="en">Yang W.L., Kouyos R., Scherrer A.U. et al. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV Cohort Study from 1998 to 2012. J Infect Dis. 2015; 212(1): 28–38. DOI: 10.1093/infdis/jiv012. Epub 2015 Jan 9; https://www.ncbi.nlm.nih.gov/pubmed/25576600</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">De Luca A., Dunn D., Zazzi M. et al. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 2013; 207(8): 1216 – 1220. DOI: 10.1093/infdis/jit017. Epub 2013 Jan 11; https://www.ncbi.nlm.nih.gov/pubmed/23315324</mixed-citation><mixed-citation xml:lang="en">De Luca A., Dunn D., Zazzi M. et al. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 2013; 207(8): 1216 – 1220. DOI: 10.1093/infdis/jit017. Epub 2013 Jan 11; https://www.ncbi.nlm.nih.gov/pubmed/23315324</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Montaner J.S., Lima V.D., Harrigan P.R. et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV treatment as prevention” experience in a Canadian setting. PLoS One. 2014; DOI:10.1371/journal.pone.0087872; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087872</mixed-citation><mixed-citation xml:lang="en">Montaner J.S., Lima V.D., Harrigan P.R. et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV treatment as prevention” experience in a Canadian setting. PLoS One. 2014; DOI:10.1371/journal.pone.0087872; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087872</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rhee S.Y., Blanco J.L., Jordan M.R. et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis. PLoS Med. 2015; DOI: 10.1371/journal.pmed.1001810; https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001810</mixed-citation><mixed-citation xml:lang="en">Rhee S.Y., Blanco J.L., Jordan M.R. et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015; DOI: 10.1371/journal.pmed.1001810; https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001810</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pham Q.D., Wilson D.P., Law M.G. et. al. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS. 2014; 28(218): 2751–2762. DOI: 10.1097/QAD.0000000000000494; https://www.ncbi.nlm.nih.gov/pubmed/25493601</mixed-citation><mixed-citation xml:lang="en">Pham Q.D., Wilson D.P., Law M.G. et. al. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS. 2014; 28(218): 2751–2762. DOI: 10.1097/QAD.0000000000000494; https://www.ncbi.nlm.nih.gov/pubmed/25493601</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hofstra L.M., Sauvageot N., Albert J. et al. Hofstra, L.M. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016; 62(5): 655–663. DOI: 10.1093/cid/civ963; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741360/</mixed-citation><mixed-citation xml:lang="en">Hofstra L.M., Sauvageot N., Albert J. et al. Hofstra, L.M. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016; 62(5): 655–663. DOI: 10.1093/cid/civ963; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741360/</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Manosuthi W., Tongyen S., Nilkamhang S. et al. HIV-1 drug resistance-associated mutations among antiretroviralnaive thai patients with chronic HIV-1 infection. J Med Virol. 2013; 85(2): 194–199. DOI: 10.1002/jmv.23452; https://www.ncbi.nlm.nih.gov/pubmed/23161095</mixed-citation><mixed-citation xml:lang="en">Manosuthi W., Tongyen S., Nilkamhang S. et al. HIV-1 drug resistance-associated mutations among antiretroviralnaive thai patients with chronic HIV-1 infection. J Med Virol. 2013; 85(2): 194–199. DOI: 10.1002/jmv.23452; https://www.ncbi.nlm.nih.gov/pubmed/23161095</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Update on HIV-1 Strain and Transmitted Drug Resistance in Canada: Findings from the Canadian HIV Strain and Drug Resistance Surveillance Program, 2012-2013. Ottawa, Canada. 2017; https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-сonditions/hiv-canadian-strain-drug-resistance-surveillance-2012-2013/hiv-canadian-strain-drug-resistance-surveillance-2012-2013.pdf</mixed-citation><mixed-citation xml:lang="en">Update on HIV-1 Strain and Transmitted Drug Resistance in Canada: Findings from the Canadian HIV Strain and Drug Resistance Surveillance Program, 2012-2013. Ottawa, Canada. 2017; https://www.canada.ca/content/dam/phac-аspc/documents/services/publications/diseases-conditions/hiv-canadian-strain-drug-resistance-surveillance-2012-2013/hiv-canadian-strain-drug-resistance-surveillance-2012-2013.pdf</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bennett D.E., Myatt M., Bertagnolio S. et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral Ther. 2008; 13(2): 25–36. https://www.ncbi.nlm.nih.gov/pubmed/18575189</mixed-citation><mixed-citation xml:lang="en">Bennett D.E., Myatt M., Bertagnolio S. et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral Ther. 2008; 13(2): 25–36. https://www.ncbi.nlm.nih.gov/pubmed/18575189</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sax P., Islam R., Walensky R. et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005; 41(9): 1316–1323. DOI: 10.1086/496984; https://academic.oup.com/cid/article/41/9/1316/278613</mixed-citation><mixed-citation xml:lang="en">Sax P., Islam R., Walensky R. et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005; 41(9): 1316–1323. DOI: 10.1086/496984; https://academic.oup.com/cid/article/41/9/1316/278613</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wittkop L., Günthard H.F., F de Wolf et al. EuroCoordCHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011; 11(5): 363-371. DOI: 10.1016/S1473-3099(11)70032-9; https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70032-9/fulltext</mixed-citation><mixed-citation xml:lang="en">Wittkop L., Günthard H.F., F de Wolf et al. EuroCoordCHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011; 11(5): 363-371. DOI: 10.1016/S1473-3099(11)70032-9; https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70032-9/fulltext</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999; 41: 95-98. http://brownlab.mbio.ncsu.edu/JWB/papers/1999Hall1.pdf</mixed-citation><mixed-citation xml:lang="en">Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999; 41: 95-98. http://brownlab.mbio.ncsu.edu/JWB/papers/1999Hall1.pdf</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tamura K., Stecher G., Peterson D. et al. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013; 30(12): 2725-2729. DOI: 10.1093/molbev/mst197; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840312/</mixed-citation><mixed-citation xml:lang="en">Tamura K., Stecher G., Peterson D. et al. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013; 30(12): 2725-2729. DOI: 10.1093/molbev/mst197; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840312/</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tang, M.W., Liu T.F., Shafer R.W. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012; 55: 98–101. DOI: 10.1159/000331998; https://pdfs.semanticscholar.org/4766/154290625737287fc25888edfee35495c4fc.pdf</mixed-citation><mixed-citation xml:lang="en">Tang, M.W., Liu T.F., Shafer R.W. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012; 55: 98–101. DOI: 10.1159/000331998; https://pdfs.semanticscholar.org/4766/154290625737287fc25888edfee35495c4fc.pdf</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bennett D.E., Camacho R.J., Otelea D. et al Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE 2009; DOI: 10.1371/journal.pone.0004724; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004724</mixed-citation><mixed-citation xml:lang="en">Bennett D.E., Camacho R.J., Otelea D. et al Drug Resistance Mutations for  Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE 2009; DOI: 10.1371/journal.pone.0004724; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004724</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Гашникова, Н.М. Молекулярно-эпидемиологическая характеристика распространения ВИЧ-инфекции на Юге России. / Н.М. Гашникова [и др.] // ВИЧ-инфекция и иммуносупрессии. – 2013. – № 5(4). – С. 73–81.</mixed-citation><mixed-citation xml:lang="en">Gashnikova, N.M. Molekulyarno-epidemiologicheskaya harakteristika rasprostraneniya VICH-infekcii na YUge Rossii. / N.M. Gashnikova [i dr.] // VICH-infekciya i immunosupressii. – 2013. – № 5(4). – S. 73–81.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Суханова, А.Л. Полиморфизм области генома, кодирующей протеазу и обратную транскриптазу, вариантов ВИЧ-1 подтипа А, распространенных на территории СНГ. / А.Л. Суханова [и др.] // Молекулярная биология. – 2005. – № 39(6). – С. 1063–1071.</mixed-citation><mixed-citation xml:lang="en">Suhanova, A.L. Polimorfizm oblasti genoma, kodiruyushchej proteazu i obratnuyu transkriptazu, variantov VICH-1 podtipa A, rasprostranennyh na territorii SNG. / A.L. Suhanova [i dr.] // Molekulyarnaya biologiya. – 2005. – № 39(6). – S. 1063–1071.19. Tang M.W., Shafer R.W. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012; 72(9): e1–e25. DOI: 10.2165/11633630-000000000-00000; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689909/</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tang M.W., Shafer R.W. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012; 72(9): e1–e25. DOI: 10.2165/11633630-000000000-00000; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689909/</mixed-citation><mixed-citation xml:lang="en">Gashnikova N.M., Astakhova E.M., Gashnikova M.P. et al. HIV-1 Epidemiology, Genetic Diversity, and Primary Drug Resistance in the Tyumen Oblast, Russia. Biomed Res Int. 2016; DOI: 10.1155/2016/2496280; https://www.hindawi.com/journals/bmri/2016/2496280/</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Gashnikova N.M., Astakhova E.M., Gashnikova M.P. et al. HIV-1 Epidemiology, Genetic Diversity, and Primary Drug Resistance in the Tyumen Oblast, Russia. Biomed Res Int. 2016; DOI: 10.1155/2016/2496280; https://www.hindawi.com/journals/bmri/2016/2496280/</mixed-citation><mixed-citation xml:lang="en">Lebedev, A.V. Cravnitel’nyj analiz geneticheskih variantov VICH-1,  cirkulirovavshih v Irkutskoj oblasti v 1999 i 2012 gg. / A.V. Lebedev [i dr.] // Problemy virusologii. – 2016. – № 61(3). – С. 112-118. DOI: 10.18821/0507-4088-2016-61-3-112-118; https://cyberleninka.ru/article/n/sravnitelnyy-analizgeneticheskih-variantov-vich-1-tsirkulirovavshih-v-irkutskoyoblasti-v-1999-i-2012-gg</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Лебедев, А.В. Cравнительный анализ генетических вариантов ВИЧ-1, циркулировавших в Иркутской области в 1999 и 2012 гг. / А.В. Лебедев [и др.] // Проблемы вирусологии. – 2016. – № 61(3). – С. 112–118. DOI: 10.18821/0507-4088-2016-61-3-112-118; https://cyberleninka.ru/article/n/sravnitelnyy-analiz-geneticheskih-variantovvich-1-tsirkulirovavshih-v-irkutskoy-oblasti-v-1999-i-2012-gg</mixed-citation><mixed-citation xml:lang="en">Kolomeets A.N., Varghese V., Lemey P. et.al. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. AIDS. 2014; 28(17): F1–F8. DOI: 10.1097/QAD.0000000000000485; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393743/</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kolomeets A.N., Varghese V., Lemey P. et.al. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. AIDS. 2014; 28(17): F1–F8. DOI: 10.1097/QAD.0000000000000485; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393743/</mixed-citation><mixed-citation xml:lang="en">Kolomeec, A.N. Epidemiologicheskie i molekulyarnogeneticheskie osobennosti VICH u inficirovannyh lic na territorii Sibirskogo federal›nogo okruga / A.N. Kolomeec [i  dr.] // MediAl›. – 2016. – № 1(18): S. 16–20. https://www.medialjournal.ru/jour/article/view/3/4</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Коломеец, А.Н. Эпидемиологические и молекулярногенетические особенности ВИЧ у инфицированных лиц на территории Сибирского федерального округа / А.Н. Коломеец [и др.] // МедиАль. – 2016. – № 1(18): С. 16–20. https://www.medial-journal.ru/jour/article/view/3/4</mixed-citation><mixed-citation xml:lang="en">Kazennova E.V., Laga V.Ye., Lapovok I.A. et al. HIV-1 genetic variants in the Russian far east. AIDS Research and Human Retroviruses. 2014; 30(8): 742–752. DOI: 10.1089/aid.2013.0194; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118705/</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kazennova E.V., Laga V.Ye., Lapovok I.A. et al. HIV-1 genetic variants in the Russian far east. AIDS Research and Human Retroviruses. 2014; 30(8): 742–752. DOI: 10.1089/aid.2013.0194; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118705/</mixed-citation><mixed-citation xml:lang="en">Vázquez De Parga, Rakhmanova A., Pérez-Álvarez L. et al E. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union. J Med Virol. 2005; 77(3): 337–344. DOI: 10.1002/jmv.20461; https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20461</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Vázquez De Parga, Rakhmanova A., Pérez-Álvarez L. et al E. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union. J Med Virol. 2005; 77(3): 337–344. DOI: 10.1002/jmv.20461; https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20461</mixed-citation><mixed-citation xml:lang="en">Gashnikova N.M., Zyryanova D.P., Astakhova E.M. et al. Predominance of CRF63 02A1 and multiple patterns of unique recombinant forms of CRF63 A1 among individuals with newly diagnosed HIV-1 infection in Kemerovo Oblast, Russia. Arch Virol. 2016; 162(2): 379-390. DOI: 10.1007/s00705-016-3120-4;  https://link.springer.com/article/10.1007/s00705-016-3120-4</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gashnikova N.M., Zyryanova D.P., Astakhova E.M. et al. Predominance of CRF63 02A1 and multiple patterns of unique recombinant forms of CRF63 A1 among individuals with newly diagnosed HIV-1 infection in Kemerovo Oblast, Russia. Arch Virol. 2016; 162(2): 379-390. DOI: 10.1007/s00705-016-3120-4; https://link.springer.com/article/10.1007/s00705-016-3120-4</mixed-citation><mixed-citation xml:lang="en">Gashnikova N.M., Zyryanova D.P., Astakhova E.M. et al. Predominance of CRF63 02A1 and multiple patterns of unique recombinant forms of CRF63 A1 among individuals with newly diagnosed HIV-1 infection in Kemerovo Oblast, Russia. Arch Virol. 2016; 162(2): 379-390. DOI: 10.1007/s00705-016-3120-4; https://link.springer.com/article/10.1007/s00705-016-3120-4</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
